Jacobs Levy Equity Management’s GoodRx Holdings GDRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-336,972
Closed -$913K 1005
2025
Q4
$913K Sell
336,972
-265,933
-44% -$873K ﹤0.01% 698
2025
Q3
$2.55M Sell
602,905
-226,193
-27% -$994K 0.01% 544
2025
Q2
$4.13M Buy
829,098
+12,377
+2% +$53.8K 0.02% 483
2025
Q1
$3.6M Sell
816,721
-244,740
-23% -$1.15M 0.01% 530
2024
Q4
$4.94M Buy
1,061,461
+798,261
+303% +$4.39M 0.02% 435
2024
Q3
$1.83M Sell
263,200
-30,398
-10% -$239K 0.01% 623
2024
Q2
$2.29M Buy
+293,598
New +$2.17M 0.01% 578
2024
Q1
Sell
-260,546
Closed -$1.75M 982
2023
Q4
$1.75M Sell
260,546
-585,177
-69% -$3.3M 0.01% 621
2023
Q3
$4.76M Sell
845,723
-362,955
-30% -$2.42M 0.03% 386
2023
Q2
$6.67M Buy
1,208,678
+170,514
+16% +$918K 0.04% 333
2023
Q1
$6.49M Sell
1,038,164
-96,446
-9% -$538K 0.04% 348
2022
Q4
$5.29M Sell
1,134,610
-311,593
-22% -$1.54M 0.04% 384
2022
Q3
$6.75M Buy
+1,446,203
New +$9.12M 0.05% 332

Other funds holding GDRX

Jacobs Levy Equity Management's GDRX Position: Q1 2026 in Review

Jacobs Levy Equity Management sold out of GoodRx Holdings (GDRX) in Q1 2026, closing a stake of 336,972 shares — an estimated $913K sold.

Jacobs Levy Equity Management first reported a position in GDRX in Q3 2022 and held it in 13 quarters. The position peaked at $6.75M in Q3 2022. 174 funds tracked by Wall St. Rank hold GDRX as of Q1 2026.

  • Jacobs Levy Equity Management reported no remaining GoodRx Holdings position as of Q1 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 336,972 GoodRx Holdings shares in Q1 2026, an estimated $913K.
  • Jacobs Levy Equity Management first reported a position in GoodRx Holdings in Q3 2022 and held it in 13 quarters.
  • Jacobs Levy Equity Management's GoodRx Holdings position peaked at $6.75M in Q3 2022.
  • 174 funds tracked by Wall St. Rank held GoodRx Holdings as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.